SILK News and Press, Silk Road Medical Inc. From 06/11/19

SUNNYVALE, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming BMO Capital Markets 2019 Prescriptions for Success Heal...

SUNNYVALE, Calif. , June 04, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced key data from the SVS TCAR Surveillance Project and ROADSTER-2 study will be presented at the upcomi...

DENVER, Colo., May 14, 2019- (24/7MarketNews via COMTEX) The following are among yesterday’s new 52 week high notables. Kraig Biocraft Laboratories Inc. (OTCQB:KBLB)- New high $0.507, previous high $0.35. Silk Road Medical Inc. (NASDAQ:SILK)- New high $46.32, previous high $45.53. Bios...

Silk Road Medical, Inc. (SILK) Q1 2019 Earnings Conference Call May 8, 2019 17:00 ET Company Participants Lynn Lewis - IR Erica Rogers - President & CEO Lucas Buchanan - CFO Conference Call Participants Bob Hopkins - Bank of America Merrill Lynch Rick Wise - Stifel Ni...

Silk Road Medical (NASDAQ: SILK ): Q1 EPS of -$20.12 may not be comparable to consensus of -$0.32. More news on: Silk Road Medical, Inc, Earnings news and commentary, Healthcare stocks news, Read more ...

SUNNYVALE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2019. Recent Highlights Recorded revenues of...

SUNNYVALE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming Bank of America Merrill Lynch 2019 Health Care Conferenc...

SUNNYVALE, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2019 after market close on Wednesday, May 8, 2019...

NGM Biopharmaceuticals (NASDAQ: NGM ) initiated with Buy rating $29 (85% upside) price target at Citigroup. Initiated with Outperform rating and $25 price target at Cowen. Initiated with Buy rating and $22 price target at Goldman Sachs. More news on: NGM Biopharmaceuticals, Inc., Silk Road...

SUNNYVALE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the closing of its initial public offering of 6,000,000 shares of ...